Floatz logo

24 assets in Immune System Disorder

Therapeutic assets addressing Immune System Disorder, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Cyclophosphamide
Immune System Disorder
Indapta Therapeutics, INC.P2BB (67)
Fludarabine
Immune System Disorder
Indapta Therapeutics, INC.P2BB (65)
Alemtuzumab
Immune System Disorder
Washington University School of MedicineP2B (60)
Ibrutinib
Immune System Disorder
Oncternal Therapeutics, IncP3B (60)
Melphalan
Immune System Disorder
Washington University School of MedicineP2B (60)
Thiotepa
Immune System Disorder
Washington University School of MedicineP2B (60)
Zilovertamab
Immune System Disorder
Oncternal Therapeutics, IncP3B (60)
Apsolol
Immune System Disorder
Tianjin Medical University General HospitalP2CCC (53)
Atl-Ric
Immune System Disorder
National Cancer Institute (NCI)P2CCC (53)
Ceftriaxone
Immune System Disorder
Tianjin Medical University General HospitalP2CCC (53)
Ioc
Immune System Disorder
National Cancer Institute (NCI)P2CCC (53)
Ivarmacitinib
Immune System Disorder
Chunxia SuP2CCC (53)
Atlcar.Cd30.Ccr4 Cells
Immune System Disorder
UNC Lineberger Comprehensive Cancer CenterP1CC (43)
Bendamustine
Immune System Disorder
UNC Lineberger Comprehensive Cancer CenterP1CC (43)
car138 t cells
Immune System Disorder
UNC Lineberger Comprehensive Cancer CenterP1CC (43)
ic9-car19 t cells
Immune System Disorder
UNC Lineberger Comprehensive Cancer CenterP1CC (43)
Idp-023
Immune System Disorder
Indapta Therapeutics, INC.P1CC (43)
Kln-1010
Immune System Disorder
Kelonia Therapeutics, Inc.P1CC (43)
Mesna
Immune System Disorder
Indapta Therapeutics, INC.P1CC (43)
Ocrelizumab
Immune System Disorder
Indapta Therapeutics, INC.P1CC (43)
Oricar-017
Immune System Disorder
OriCell Therapeutics Co., Ltd.P1CC (43)
Rimiducid
Immune System Disorder
UNC Lineberger Comprehensive Cancer CenterP1CC (43)
Vitamin D
Immune System Disorder
Suzhou Municipal Hospital of Anhui ProvinceEarly P1CC (43)
L-Bupivacaine
Immune System Disorder
University of RijekaN/AD (30)